| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | NK4; TAIF; TAIFa; TAIFb; TAIFc; TAIFd; IL-32beta; IL-32alpha; IL-32delta; IL-32gamma |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL32 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL-32抗体的参考文献示例(内容仅供示例参考，实际文献可能存在差异)：
1. **"IL-32 Monoclonal Antibody Attenuates Inflammation in Collagen-Induced Arthritis"**
*作者：Kim et al. (2015)*
**摘要**：研究开发了一种靶向IL-32的单克隆抗体，通过抑制IL-32与整合素相互作用，显著降低胶原诱导关节炎模型中的炎症反应和关节损伤。
2. **"The Role of IL-32 in Cancer: Development of a Neutralizing Antibody for Therapeutic Use"**
*作者：Chen et al. (2018)*
**摘要**：该文献报道了一种新型中和性IL-32抗体的开发，证明其可通过阻断IL-32γ亚型信号通路抑制肿瘤细胞增殖，并在肺癌小鼠模型中减少转移。
3. **"IL-32-Specific Antibody Detection in HIV-Infected Patients: Implications for Chronic Inflammation"**
*作者：Smith et al. (2020)*
**摘要**：研究利用IL-32特异性抗体检测HIV患者血清中的IL-32水平，发现其与疾病进展和慢性炎症标志物(如CRP)呈正相关，提示IL-32可能作为治疗靶点。
4. **"Structural Characterization of a Humanized Anti-IL-32 Antibody for Inflammatory Bowel Disease"**
*作者：Wang et al. (2021)*
**摘要**：通过人源化改造优化了抗IL-32抗体的结合亲和力，并在细胞实验和小鼠结肠炎模型中验证其抑制促炎因子(如TNF-α、IL-6)释放的能力。
**注意**：以上文献名称和内容为示例性概括，具体研究需参考真实数据库(如PubMed、ScienceDirect)。建议通过关键词“IL-32 antibody”或“Interleukin-32 therapeutic”检索最新文献。
IL32 (Interleukin-32) is a proinflammatory cytokine first identified in 2005. encoded by the IL32 gene on human chromosome 16. Unlike classical interleukins, IL32 lacks a signal peptide but exerts diverse immunomodulatory roles by inducing other cytokines (e.g., TNF-α, IL-6. IL-1β) via NF-κB and p38 MAPK pathways. It exists in six splice variants (IL-32α to IL-32ζ), with IL-32γ being the most biologically active form. IL32 is expressed in immune cells (T cells, NK cells), epithelial tissues, and inflamed sites, and is implicated in autoimmune diseases, infections, and cancer.
IL32 antibodies are critical tools for detecting IL32 isoforms and studying their functional roles. They enable quantification of IL32 in clinical samples (e.g., serum, tissues) and facilitate mechanistic studies via neutralization or immunohistochemistry. Commercial IL32 antibodies are typically developed in rabbits or mice, targeting specific epitopes (e.g., N-terminal regions for isoform differentiation). Validation includes Western blot, ELISA, and flow cytometry. Challenges include cross-reactivity between isoforms and variability due to post-translational modifications. Recent research highlights IL32's dual role in cancer—promoting tumor growth in some contexts (e.g., lung cancer) while enhancing antitumor immunity in others—making IL32 antibodies valuable for both diagnostic and therapeutic exploration.
×
